QualityStocksNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances GEP-44 Toward IND-Enabling Studies, Expands Investor Outreach
This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF) announced plans to initiate a U.S. Food and Drug Administration IND-enabling GLP toxicology and pharmacology program for its lead candidate GEP-44, to be conducted with LabCorp, aimed at supporting future Phase I clinical trials. The studies are designed to assess safety, dosing parameters and biomarkers across multiple species as the company advances its GLP-1 agonist peptide targeting Type II diabetes and obesity. The company also outlined expanded investor outreach initiatives, including a strategic agreement with Investor Brand Network (IBN)…
